PRAME expression and clinical outcome of breast cancer

The tumour antigen PReferentially expressed Antigen of MElanoma (PRAME) is expressed in a variety of malignancies, including breast cancer. We have analysed PRAME gene expression in relation to clinical outcome for 295 primary breast cancer patients. Kaplan–Meier survival curves show a correlation o...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 2008-08, Vol.99 (3), p.398-403
Main Authors: Epping, M T, Hart, A A M, Glas, A M, Krijgsman, O, Bernards, R
Format: Article
Language:English
Subjects:
Antigens, Neoplasm - genetics
Biological and medical sciences
Biomedical and Life Sciences
Biomedicine
Breast cancer
Breast Neoplasms - genetics
Cancer Research
Clinical outcomes
Clinical Study
Drug Resistance
Epidemiology
Gene Expression Profiling
Gynecology. Andrology. Obstetrics
Humans
Mammary gland diseases
Medical sciences
Molecular Medicine
Multivariate Analysis
Oligonucleotide Array Sequence Analysis
Oncology
Prognosis
Proportional Hazards Models
Survival Analysis
Treatment Outcome
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c551t-3c346b03898cb628a73efa5adc845739fc9dcac51e07f3833e11e01deaa9ad063
cites cdi_FETCH-LOGICAL-c551t-3c346b03898cb628a73efa5adc845739fc9dcac51e07f3833e11e01deaa9ad063
container_end_page 403
container_issue 3
container_start_page 398
container_title British journal of cancer
container_volume 99
creator Epping, M T
Hart, A A M
Glas, A M
Krijgsman, O
Bernards, R
description The tumour antigen PReferentially expressed Antigen of MElanoma (PRAME) is expressed in a variety of malignancies, including breast cancer. We have analysed PRAME gene expression in relation to clinical outcome for 295 primary breast cancer patients. Kaplan–Meier survival curves show a correlation of PRAME expression levels with increased rates of distant metastases and decreased overall patient survival. This correlation existed both for the entire patient group ( n =295) and for the subgroup of patients ( n =185) who did not receive adjuvant chemotherapy. Multivariable analysis indicated that PRAME is an independent marker of shortened metastasis-free interval in patients who did not receive adjuvant chemotherapy. PRAME expression was associated with tumour grade and negative oestrogen receptor status. We conclude that PRAME expression is a prognostic marker for clinical outcome of breast cancer, independent of traditional clinicopathological markers.
doi_str_mv 10.1038/sj.bjc.6604494
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2527791</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1521265621</sourcerecordid><originalsourceid>FETCH-LOGICAL-c551t-3c346b03898cb628a73efa5adc845739fc9dcac51e07f3833e11e01deaa9ad063</originalsourceid><addsrcrecordid>eNp1kM1LwzAYh4Mobk6vHqUIHlvz0aTJRRhjfsBEET2HNE1nS9fMpBX9781Y2fTgKQnvk_f34wHgHMEEQcKvfZ3ktU4Yg2kq0gMwRpTgGHGcHYIxhDCLocBwBE68r8NTQJ4dgxHiLOWE0TFgzy_Tx3lkvtbOeF_ZNlJtEemmaiutmsj2nbYrE9kyyp1Rvou0arVxp-CoVI03Z8M5AW-389fZfbx4unuYTRexphR1MdEkZXnoKbjOGeYqI6ZUVBWapzQjotSi0EpTZGBWEk6IQeGKCqOUUAVkZAJutnvXfb4yhTZt51Qj165aKfctrark30lbvcul_ZSY4iwTKCy4HBY4-9Eb38na9q4NnSUmECLBGQlQsoW0s947U-4CEJQbzdLXMmiWg-bw4eJ3rT0-eA3A1QAoHzyWLlir_I7DkPLgZJN8veV8GLVL4_b1_on-AWpblmE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>230019863</pqid></control><display><type>article</type><title>PRAME expression and clinical outcome of breast cancer</title><source>PubMed Central Free</source><creator>Epping, M T ; Hart, A A M ; Glas, A M ; Krijgsman, O ; Bernards, R</creator><creatorcontrib>Epping, M T ; Hart, A A M ; Glas, A M ; Krijgsman, O ; Bernards, R</creatorcontrib><description>The tumour antigen PReferentially expressed Antigen of MElanoma (PRAME) is expressed in a variety of malignancies, including breast cancer. We have analysed PRAME gene expression in relation to clinical outcome for 295 primary breast cancer patients. Kaplan–Meier survival curves show a correlation of PRAME expression levels with increased rates of distant metastases and decreased overall patient survival. This correlation existed both for the entire patient group ( n =295) and for the subgroup of patients ( n =185) who did not receive adjuvant chemotherapy. Multivariable analysis indicated that PRAME is an independent marker of shortened metastasis-free interval in patients who did not receive adjuvant chemotherapy. PRAME expression was associated with tumour grade and negative oestrogen receptor status. We conclude that PRAME expression is a prognostic marker for clinical outcome of breast cancer, independent of traditional clinicopathological markers.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/sj.bjc.6604494</identifier><identifier>PMID: 18648365</identifier><identifier>CODEN: BJCAAI</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Antigens, Neoplasm - genetics ; Biological and medical sciences ; Biomedical and Life Sciences ; Biomedicine ; Breast cancer ; Breast Neoplasms - genetics ; Cancer Research ; Clinical outcomes ; Clinical Study ; Drug Resistance ; Epidemiology ; Gene Expression Profiling ; Gynecology. Andrology. Obstetrics ; Humans ; Mammary gland diseases ; Medical sciences ; Molecular Medicine ; Multivariate Analysis ; Oligonucleotide Array Sequence Analysis ; Oncology ; Prognosis ; Proportional Hazards Models ; Survival Analysis ; Treatment Outcome ; Tumors</subject><ispartof>British journal of cancer, 2008-08, Vol.99 (3), p.398-403</ispartof><rights>The Author(s) 2008</rights><rights>2008 INIST-CNRS</rights><rights>Copyright Nature Publishing Group Aug 5, 2008</rights><rights>Copyright © 2008 Cancer Research UK 2008 Cancer Research UK</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c551t-3c346b03898cb628a73efa5adc845739fc9dcac51e07f3833e11e01deaa9ad063</citedby><cites>FETCH-LOGICAL-c551t-3c346b03898cb628a73efa5adc845739fc9dcac51e07f3833e11e01deaa9ad063</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2527791/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2527791/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=20588983$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18648365$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Epping, M T</creatorcontrib><creatorcontrib>Hart, A A M</creatorcontrib><creatorcontrib>Glas, A M</creatorcontrib><creatorcontrib>Krijgsman, O</creatorcontrib><creatorcontrib>Bernards, R</creatorcontrib><title>PRAME expression and clinical outcome of breast cancer</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><addtitle>Br J Cancer</addtitle><description>The tumour antigen PReferentially expressed Antigen of MElanoma (PRAME) is expressed in a variety of malignancies, including breast cancer. We have analysed PRAME gene expression in relation to clinical outcome for 295 primary breast cancer patients. Kaplan–Meier survival curves show a correlation of PRAME expression levels with increased rates of distant metastases and decreased overall patient survival. This correlation existed both for the entire patient group ( n =295) and for the subgroup of patients ( n =185) who did not receive adjuvant chemotherapy. Multivariable analysis indicated that PRAME is an independent marker of shortened metastasis-free interval in patients who did not receive adjuvant chemotherapy. PRAME expression was associated with tumour grade and negative oestrogen receptor status. We conclude that PRAME expression is a prognostic marker for clinical outcome of breast cancer, independent of traditional clinicopathological markers.</description><subject>Antigens, Neoplasm - genetics</subject><subject>Biological and medical sciences</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - genetics</subject><subject>Cancer Research</subject><subject>Clinical outcomes</subject><subject>Clinical Study</subject><subject>Drug Resistance</subject><subject>Epidemiology</subject><subject>Gene Expression Profiling</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Mammary gland diseases</subject><subject>Medical sciences</subject><subject>Molecular Medicine</subject><subject>Multivariate Analysis</subject><subject>Oligonucleotide Array Sequence Analysis</subject><subject>Oncology</subject><subject>Prognosis</subject><subject>Proportional Hazards Models</subject><subject>Survival Analysis</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><recordid>eNp1kM1LwzAYh4Mobk6vHqUIHlvz0aTJRRhjfsBEET2HNE1nS9fMpBX9781Y2fTgKQnvk_f34wHgHMEEQcKvfZ3ktU4Yg2kq0gMwRpTgGHGcHYIxhDCLocBwBE68r8NTQJ4dgxHiLOWE0TFgzy_Tx3lkvtbOeF_ZNlJtEemmaiutmsj2nbYrE9kyyp1Rvou0arVxp-CoVI03Z8M5AW-389fZfbx4unuYTRexphR1MdEkZXnoKbjOGeYqI6ZUVBWapzQjotSi0EpTZGBWEk6IQeGKCqOUUAVkZAJutnvXfb4yhTZt51Qj165aKfctrark30lbvcul_ZSY4iwTKCy4HBY4-9Eb38na9q4NnSUmECLBGQlQsoW0s947U-4CEJQbzdLXMmiWg-bw4eJ3rT0-eA3A1QAoHzyWLlir_I7DkPLgZJN8veV8GLVL4_b1_on-AWpblmE</recordid><startdate>20080805</startdate><enddate>20080805</enddate><creator>Epping, M T</creator><creator>Hart, A A M</creator><creator>Glas, A M</creator><creator>Krijgsman, O</creator><creator>Bernards, R</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>5PM</scope></search><sort><creationdate>20080805</creationdate><title>PRAME expression and clinical outcome of breast cancer</title><author>Epping, M T ; Hart, A A M ; Glas, A M ; Krijgsman, O ; Bernards, R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c551t-3c346b03898cb628a73efa5adc845739fc9dcac51e07f3833e11e01deaa9ad063</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Antigens, Neoplasm - genetics</topic><topic>Biological and medical sciences</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - genetics</topic><topic>Cancer Research</topic><topic>Clinical outcomes</topic><topic>Clinical Study</topic><topic>Drug Resistance</topic><topic>Epidemiology</topic><topic>Gene Expression Profiling</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Mammary gland diseases</topic><topic>Medical sciences</topic><topic>Molecular Medicine</topic><topic>Multivariate Analysis</topic><topic>Oligonucleotide Array Sequence Analysis</topic><topic>Oncology</topic><topic>Prognosis</topic><topic>Proportional Hazards Models</topic><topic>Survival Analysis</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Epping, M T</creatorcontrib><creatorcontrib>Hart, A A M</creatorcontrib><creatorcontrib>Glas, A M</creatorcontrib><creatorcontrib>Krijgsman, O</creatorcontrib><creatorcontrib>Bernards, R</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Epping, M T</au><au>Hart, A A M</au><au>Glas, A M</au><au>Krijgsman, O</au><au>Bernards, R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>PRAME expression and clinical outcome of breast cancer</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><addtitle>Br J Cancer</addtitle><date>2008-08-05</date><risdate>2008</risdate><volume>99</volume><issue>3</issue><spage>398</spage><epage>403</epage><pages>398-403</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><coden>BJCAAI</coden><abstract>The tumour antigen PReferentially expressed Antigen of MElanoma (PRAME) is expressed in a variety of malignancies, including breast cancer. We have analysed PRAME gene expression in relation to clinical outcome for 295 primary breast cancer patients. Kaplan–Meier survival curves show a correlation of PRAME expression levels with increased rates of distant metastases and decreased overall patient survival. This correlation existed both for the entire patient group ( n =295) and for the subgroup of patients ( n =185) who did not receive adjuvant chemotherapy. Multivariable analysis indicated that PRAME is an independent marker of shortened metastasis-free interval in patients who did not receive adjuvant chemotherapy. PRAME expression was associated with tumour grade and negative oestrogen receptor status. We conclude that PRAME expression is a prognostic marker for clinical outcome of breast cancer, independent of traditional clinicopathological markers.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>18648365</pmid><doi>10.1038/sj.bjc.6604494</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0007-0920
ispartof British journal of cancer, 2008-08, Vol.99 (3), p.398-403
issn 0007-0920
1532-1827
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2527791
source PubMed Central Free
subjects Antigens, Neoplasm - genetics
Biological and medical sciences
Biomedical and Life Sciences
Biomedicine
Breast cancer
Breast Neoplasms - genetics
Cancer Research
Clinical outcomes
Clinical Study
Drug Resistance
Epidemiology
Gene Expression Profiling
Gynecology. Andrology. Obstetrics
Humans
Mammary gland diseases
Medical sciences
Molecular Medicine
Multivariate Analysis
Oligonucleotide Array Sequence Analysis
Oncology
Prognosis
Proportional Hazards Models
Survival Analysis
Treatment Outcome
Tumors
title PRAME expression and clinical outcome of breast cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T05%3A47%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=PRAME%20expression%20and%20clinical%20outcome%20of%20breast%20cancer&rft.jtitle=British%20journal%20of%20cancer&rft.au=Epping,%20M%20T&rft.date=2008-08-05&rft.volume=99&rft.issue=3&rft.spage=398&rft.epage=403&rft.pages=398-403&rft.issn=0007-0920&rft.eissn=1532-1827&rft.coden=BJCAAI&rft_id=info:doi/10.1038/sj.bjc.6604494&rft_dat=%3Cproquest_pubme%3E1521265621%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c551t-3c346b03898cb628a73efa5adc845739fc9dcac51e07f3833e11e01deaa9ad063%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=230019863&rft_id=info:pmid/18648365&rfr_iscdi=true